Translational Research

The Vancouver Prostate Centre is heavily focused on translational research, which is the ability to move laboratory discoveries through the checks and balances into clinical trials, and eventually to develop these research findings into new and more effective treatments.

PC-TRiADD is the Vancouver Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development.

This initiative dives down to the molecular level to understand prostate cancer progression and treatment resistance and uses that information to develop new services and products to improve cancer outcomes.

Previously funded by the Government of Canada as a Centre of Excellence for Commercialization and Research (CECR), PC-TRiADD also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research.

Research2Reality interview with Dr. Gleave

Dr. Gleave discusses the role of research in the development of new drug combinations and personalized treatments for prostate cancer on Research2Reality's Orange Chair Sessions (2.5 minutes).

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Fathers Day Walk Run 2019

Raymond James Father's Day Walk Run Fundraiser, June 16, 2019

The 21st Annual Raymond James Walk Run fundraiser for Prostate Cancer Foundation BC took place on Sunday June 16, 2019 in various locations across BC. The sponsorship page is still accepting donations;  click here to sponsor our Centre's team (opens in new window).

 

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Dr. Flannigan
Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi